
|Articles|October 24, 2012
Six-gene signature predicts survival in advanced PCa
Researchers from Mount Sinai School of Medicine in New York say they have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC
2
FDA updates in urology: January 2026
3
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
4
FDA premarket approval sought for Signatera CDx test in MIBC
5






